Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1601-1620 of 1,743 trials

Leber Congenital Amaurosis: Sepofarsen Treatment Study

We are investigating a new treatment for people with Leber Congenital Amaurosis caused by a specific genetic mutation. The study will assess how well it improves vision and its safety over time.

Leber's Congenital Amaurosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesOphthalmology

Neuroinflammation in Major Depressive Disorder: InflaDep Study

We are investigating the patterns of neuroinflammation in people with major depressive disorder compared to those in remission and healthy individuals. This study may help us understand the links between inflammation and depression symptoms.

Depressive Disorder>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesPsychiatry

Ketamine for Treating Disorders of Consciousness After Coma

We are studying whether intravenous ketamine can help patients regain consciousness after a coma. The trial also aims to identify which patients may respond best to this treatment.

Severe Brain Injury and Disorder of Consciousness>2 yearsEfficacy phase (II)Standard MedicinesPartially RemoteNeurologyPsychiatry

Procizumab for Critical Cardiovascular Care

We are evaluating a new treatment for patients receiving critical care for cardiovascular issues. This study aims to understand its safety and potential benefits in this high-risk group.

Cardiogenic Shock>2 yearsSafety phase (I)CardiologyInternal Medicine

Skin Inflammation and Antibiotic Effectiveness Study

We are examining how medications cause skin inflammation and how this affects antibiotic concentration in inflamed and healthy tissues. This research may help improve treatment strategies for skin infections.

Skin Inflammation>2 yearsSafety phase (I)DermatologyInfectious Diseases

Usher Syndrome Type 1B: AAVB-081 Injection Study

We are testing a new subretinal injection for patients with Usher Syndrome Type 1B to see if it is safe and how it affects retinal health. The goal is to find a dose that balances safety and effectiveness.

Usher Syndrome Type 1B>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Glaucoma: Oral Semaglutide Study

We are investigating whether oral semaglutide can safely improve retinal function in patients with open-angle glaucoma. This research may help find new ways to protect vision in those affected by this condition.

Glaucoma>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementEndocrinologyOphthalmology

Colorectal Cancer: Intravenous Iron Infusion Study

We are investigating whether intravenous iron can improve physical capacity and immune response in non-anemic patients with colorectal cancer. This study compares the effects of iron to a placebo to understand its potential benefits.

Iron Deficiency>2 yearsEfficacy phase (II)Investigational MedicinesGastroenterologyOncology

Myoclonic Astatic Epilepsy: Fenfluramine Safety Study

We are monitoring the long-term safety of Fenfluramine as an add-on therapy for patients with Myoclonic Astatic Epilepsy. This study aims to ensure the treatment is safe and effective for managing seizures.

Myoclonic-Astatic Epilepsy>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Early Alzheimer’s Disease: AD04 Treatment Study

We are testing a new treatment called AD04 to see if it can slow the progression of early Alzheimer’s disease. The study will also evaluate the safety of AD04 and its effects on quality of life.

Early Alzheimer's Disease>2 yearsEfficacy phase (II)Investigational MedicinesNeurologyPsychiatry

Metastatic Colorectal Cancer: Cetuximab Treatment Study

We are exploring a new treatment approach using cetuximab for patients with specific genetic markers in metastatic colorectal cancer. The study aims to understand its effectiveness, safety, and impact on quality of life.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Colonoscopy Prep: Comparing Plenvu® and Picoprep®

We are studying how well Plenvu® works compared to Picoprep® for cleaning the bowel before a colonoscopy. The goal is to see which option is more effective and easier for patients to tolerate.

Healthy Participants for Colonoscopy Preparation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterology

Echinococcosis: Albendazole Study

We are examining how the medication Albendazole is processed in the body of patients with cystic and alveolar echinococcosis. This study aims to improve treatment strategies for these infections.

Human Echinococcosis>2 yearsSafety phase (I)Infectious Diseases

Hematopoietic Cell Transplantation: Comparing Conditioning Regimens

We are comparing two treatment methods for patients receiving stem cell transplants from matched donors. The goal is to see if one method improves recovery rates better than the other.

Hematological Malignancies>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Ulcerative Rectal Colitis: Tofacitinib Response Study

We are researching what factors may predict how well patients with ulcerative rectal colitis respond to Tofacitinib therapy. This could help improve treatment strategies for better patient care.

Ulcerative Colitis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Mycobacterium Avium Complex Lung Infections: Comparing Antibiotics

We are studying whether azithromycin is as effective as clarithromycin for treating lung infections caused by Mycobacterium avium complex. The trial also examines safety and side effects of both treatments.

Mycobacterium Avium Complex Infection>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Steroid Withdrawal in Systemic Lupus Erythematosus (SLE)

We are studying whether stopping glucocorticoids is as effective as continuing a low dose for patients with stable SLE. This research aims to understand the impact on disease activity and quality of life over three years.

Systemic Lupus Erythematosus>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineRheumatology

Hydroxychloroquine for Mastocytosis Symptoms

We are studying whether hydroxychloroquine can help reduce itching and flushing in patients with isolated cutaneous mastocytosis or indolent systemic mastocytosis with skin involvement. The trial also looks at other symptoms and how well patients tolerate the treatment.

Mastocytosis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesDermatologyInternal Medicine

Gastroesophageal Cancer: Sertraline with Immunochemotherapy

We are studying whether adding sertraline can enhance treatment responses in patients with advanced gastroesophageal cancer receiving immunochemotherapy. The trial also looks at safety, quality of life, and depression during treatment.

Gastroesophageal Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPsychiatry

Advanced Non-Small Cell Lung Cancer: H1-Antihistamine with Immunotherapy

We are studying whether adding an H1-antihistamine to immunotherapy can improve treatment response in patients with advanced non-small cell lung cancer.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncologyPulmonology